Discovery Life Sciences’ Post

GREAT article on MDS. Something to save to the desktop or otherwise bookmark if you’re in the Low-High Risk MDS or AML areas.

A roadmap to harmonise the two classifications (WHO and ICC) for MDS into a unified and globally adopted system. An important international effort.

"Non-invasive tests may actually hold more predictive value than imaging tests, which makes sense because they can detect disease at a much lower level...perhaps this is an opportunity to improve the way we define remission." Mark Roschewski discusses the findings and implications from his recent study presented at #ash23 that compared the performance of PhasED-Seq ctDNA vs. PET/CT scans for response assessment after frontline therapy for aggressive #DLBCL. These findings require us to rethink how we best measure response in lymphoma - and this is particularly critical for clinical trials. When used in conjunction with standard PET/CT imaging, PhasED-Seq's ultra-sensitive ctDNA platform may be a more accurate measure of response, and thereby, a more confident indicator of therapeutic efficacy for drug development and approvals. Watch the full video here: https://lnkd.in/dqJvbfw9 #mrd #ctdna #lymphoma #clinicaltrials

Vivli Researcher Spotlight: 🔦 Check out our newest update, with researcher Dr. Ashley Hopkins on using Vivli to access #individualpatientdata and making an impact in #cancertreatment: 👉 https://lnkd.in/gPNFVpRi

🔍 Exploring the MARIPOSA-2 Trial 🔍 Panelists Rahul Gosain, MD, Rohit Gosain, MD, and Stephen Liu, MD, recently delved into the objectives, study design, and significant outcomes of the MARIPOSA-2 trial. Join us as we uncover the key findings and their implications for patient care! #Oncology #MARIPOSA2 #ClinicalResearch #PatientCare https://lnkd.in/eUBedZ-w

How does the phase 3 ADRIATIC trial change the standard of care for LS-SCLC? In this #ASCO24 video interview, David R. Spigel, MD, of Sarah Cannon Research Institute, explains what clinicians should know about the study and its implications. Watch now: https://buff.ly/45BH15p #lcsm #SCLC

We are thrilled to share a recording of a GlycoNet webinar featuring Dr. Paula Videira, Co-Founder of CellmAbs, Co-director of GLYCOTwinning, and Associate Professor at Faculdade de Ciências e Tecnologia da Universidade NOVA de Lisboa. Introduced by Mr. David Firer, Chair of the GlycoNet Trainee Association – Executive Committee, Dr. Videira dives deep into "Unlocking the Glycoimmune Potential: Novel Strategies for Advanced Immunotherapy". Additionally, don’t miss the insightful presentation by her PhD student, Ms. Rita Adubeiro Lourenço, on "Deciphering the Enigmatic Role of O-glycan Signatures in Cancer". 👉 Watch the full recording here: https://lnkd.in/drFNUuS2 Learn more about GlycoNet and GLYCOTwinning and join us in advancing the field of glycomics and immunotherapy. #GlycoNet #GLYCOTwinning #Glycomics #glycobiology #CancerResearch #Glycoscience #Webinar

Don't miss our interview with Sanjay Juneja, M.D. We're covering several important topics: 1. How to catch cancer much earlier to "live long and prosper!" 2. Why current diagnostics, including genomic testing, fall short of finding the best therapy for you. 3. How the SAGE Oncotest can help you to receive the most effective treatment. https://lnkd.in/g9AAuH8v

🎉 Our CPO, Oz Huner, is giving a live demo at #ASCO24 and showcasing the transformative capabilities of the Massive Bio #ClinicalNetwork. The response has been overwhelmingly positive! 🩺 Physicians face many challenges in referring patients to clinical trials, including limited awareness of active trials and evaluating eligibility. The Massive Bio Clinical Network addresses these issues by providing up-to-date information on recruiting trials, allowing physicians to find the right trial options quickly. With Dr. Arturo AI, physicians can interactively summarize patient data and identify eligible trials in minutes. Our platform ensures accurate identification of all potential cancer trials through a systematic pre-screening and matching process, increasing the chances of successful referrals. Additionally, our free concierge services assist patients throughout the trial enrollment process. 👉🏻 We invite you to visit our booth to get more information and learn more about our products up close. Booth: #29137 Selin Kurnaz, PhD, Arturo LoAIza-Bonilla MD, Çağatay M. Çulcuoğlu, Toygun Onaran, Oz Huner, Aslan Aslanağı, Eren Caskurlu, Hakki Isik, PMP, Mert Sarı, Ertuğrul T., Toykan Dogan, MCogSc #MassiveBio #ClinicalNetwork #ClinicalResearch #CancerResearch #ArtificialIntelligence #FutureInHealth

🔬 Exciting Update on #BSMO24! Brigitte Maes shares insights into the groundbreaking #BALLETT study, powered by @mybsmo and employing TSO500 for comprehensive genomic profiling. All results from TSO interpreted by our #oncokdm software. 🧬 Key Highlights: 🔍 Actionable Variants: Detected in an impressive 83% of patients, underlining the study's precision in identifying relevant genomic information. 💡 Treatment Recommendations: Remarkably, 70% of patients received tailored treatment recommendations based on genomic profiling. ⏭️ Follow-up Success: Encouragingly, 21% of patients have already initiated the recommended treatments, emphasizing the study's impact on patient care and outcomes. 🤔 Question: When will this kind of tumor profiling be reimbursed in Belgium? The urgency for widespread access to such innovative and personalized approaches to treatment is undeniable. Kudos to the dedicated team behind #BSMO24 for advancing precision medicine and paving the way for personalized treatment strategies! 🚀🌐 #GenomicProfiling #PrecisionMedicine #HealthcareInnovation #MedicalResearch